AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?

AstraZeneca (NASDAQ: AZN) is embarking on a fresh business plan that will see it grow significantly between now and 2030. If it succeeds, it'll be a company that's even more prominent in the global biopharma sector, and its investors could potentially be wealthier too. https://www.nasdaq.com/articles/astrazeneca-plans-rake-80-billion-2030-should-you-buy-stock